Edgeline Holdings, Inc. (ELHI.OB) announced that the company has entered into an exclusive Option agreement with The University of Texas M. D. Anderson Cancer Center. This agreement will grant Edgeline Holdings exclusive rights to negotiate the licensing of five technologies over a nine month period. During this period, the company will be able to develop a specific market for each product, as well as negotiate the licensing needed for use of such patents.
“This agreement gives us the necessary time to allow our subsidiary, Intertech Bio, to properly evaluate the potential of these technologies,” stated Leonard Ivins, Chief Executive Officer of Edgeline Holdings. “M. D. Anderson has been a leader in developing new cancer therapies and we are excited about the opportunity to work with such a great institution.”
Edgeline Holdings, Inc. is a publicly traded company that specializes in discovering and acquiring leading technologies. Currently, Edgeline is focused on entering agreements with early stage companies, as such companies often require management expertise to further develop their products. In turn, Edgeline will be able to maximize the value of each company, as Edgeline can help arrange licensing arrangements and partnerships for each entity.
Let us hear your thoughts below:
